NexLife pharmacy: 503A, 503B, and what we have and have not verified
What we evaluated: NexLife's disclosed pharmacy network and its regulatory status
Date verified: July 12, 2026
Direct answer: NexLife is a telehealth company, not a pharmacy. It discloses a network of compounding pharmacies — Red Rock, Hallandale, Absolute, Empower and DIRx — which is more than most competitors will name at all
Necessary qualification: we have NOT independently verified the 503A or 503B registration of any of those facilities, and we will not assert a registration we have not confirmed. That gap applies to every provider on this site, not only NexLife
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Who is who — the distinctions this industry blurs
| Entity | What it means |
|---|---|
| Telehealth company | Arranges the consultation and the prescription. NexLife is this. Not a pharmacy, not a manufacturer |
| 503A pharmacy | State-licensed. Compounds for an individual patient against a prescription |
| 503B outsourcing facility | FDA-registered. May compound in bulk. Subject to CGMP requirements |
| Manufacturer | Makes the FDA-approved product. Eli Lilly, Novo Nordisk |
| Compounded preparation | Not FDA-approved as a finished product. No premarket review of safety, effectiveness or quality |
What NexLife discloses
NexLife names its pharmacy network: Red Rock, Hallandale, Absolute, Empower and DIRx. It also names its medical leadership: Dr. Adam Kennah, MD (NPI 1144260043, provider-supplied).
Naming the pharmacies at all puts NexLife ahead of most of this field. A large number of telehealth companies will not tell you which facility compounds the medicine you inject, and a provider that will not name its pharmacy has answered the question whether it meant to or not.
What we have NOT verified — stated plainly
Every one of those facts therefore carries a Evaluation in progress label rather than a Verified. We would rather show you the gap than paper over it — and you should be sceptical of any comparison site that claims to have verified what we have not.
What to ask NexLife — or any provider — before enrolling
Questions to ask about the pharmacy
The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.
Frequently asked questions
Is NexLife a 503A or 503B pharmacy?
NexLife is neither — it is a telehealth company, not a pharmacy. That distinction matters. NexLife discloses a pharmacy network (Red Rock, Hallandale, Absolute, Empower, DIRx), but we have NOT independently verified the 503A or 503B registration of any of those specific facilities, and we will not state a registration we have not confirmed.
What is the difference between 503A and 503B?
A 503A pharmacy is state-licensed and compounds for an individual patient against a prescription. A 503B outsourcing facility is FDA-registered, may compound in bulk, and is subject to current good manufacturing practice requirements. Registration is per-facility, not per-company — a company can use both for different products, so 'our pharmacies are 503B' is not a verifiable claim about the one filling your script.
Is NexLife's medication FDA-approved?
No. Compounded medications are not FDA-approved as finished products and the FDA does not review them for safety, effectiveness or quality before marketing. This is true of every compounded provider, not just NexLife.
Sources
- NexLife published pharmacy and medical-leadership disclosures — provider-reported, not independently verified.
- U.S. Food and Drug Administration — 503A and 503B compounding guidance; the "essentially a copy" doctrine.
- State boards of pharmacy — licensee databases (the correct place to verify a specific facility).
- Our pharmacy-evaluation methodology.